For refractory or relapsed (r/r) B-cell non-Hodgkin lymphoma (NHL), the response rates to conventional salvage chemotherapy are 27-44%. 1 Chimeric antigen receptors (CARs) efficiently redirect T-cell specificity and cytotoxicity to cells expressing the targeted Ag in an HLA-independent manner. 2 The early phase clinical trials of CART cells for (r/r) B-cell NHL have demonstrated promising results. Recent updated data from US National Cancer Institute (NCI) showed that five of the seven (71%) evaluable patients with relapsed diffuse large B-cell lymphoma (DLBCL) obtained complete remissions (CRs) after infusion of anti-CD19 CAR-T cells, and four of the five CRs had long-term durability with duration ranging from 38 to 57 months. 3 Encouraging results have also been seen in our prior studies of autologous CART-20 cells in patients with r/r CD20 + B-NHL (NCT01735604). 4, 5 This paper reports the long-term efficacy and safety of CART-20 cells in patients with r/r CD20 + B-NHL after 5-year follow-up.
From July 2012 to June 2015, a total of 17 patients with r/r B-cell NHL have been enrolled in our studies. As of July 2017, the median follow-up time was 20 months (range, 4-60 months). The patients underwent cytoreductive chemotherapy for tumor debulking and lymphodepletion between 3 and 7 days before T-cell infusion. All patients received at least one cycle CAR.20-CD137ζ transduced T cells infusion at a dose of 0.5-1.5 × 10 7 kg − 1 . Clinical trial design and assay protocols have been reported in detail in our prior publications. 4, 5 The baseline characteristics of all the patients are presented in Table 1 . Briefly, all patients were heavily pretreated and had received rituximab previously; 16 patients (94%) had received 4 or more previous treatment regimens, and 12 patients (70.6%) had relapsed after previous second-line chemotherapy regimens. One patient had relapsed post-autologous stem cell transplantation (SCT). Eleven patients (64.7%) were defined as either refractory or progressive according to their responses to recent chemotherapeutics. Fourteen patients (82.4%) were diagnosed with DLBCL and three (17.6%) had indolent lymphoma. Notably, five patients had bulky tumor burden in the phase I trial.
In phase IIa trial, 11 patients were available to evaluate the objective clinical responses. The overall objective response rate was 9 of 11 (81.8%), with 54.5% of patients (6/11) achieving CR and 27.3% (3/11) achieving partial remission (PR). One patient with PR and one patient with stable disease after CART-20 cell infusion received consolidative local radiotherapy and were subsequently converted to CR. In the phase I trial, five of six patients experienced tumor regression.
Twelve patients with remission but refusing autologous or allogeneic SCT were followed up for a median of 20 months (range, 4-60 months) from their first CART-20 cell infusion. The estimated median progression-free survival (PFS) of the 12 patients was 10 months (range, 2-57 months) ( Figure 1a ) and the estimated 2-year rate of PFS was 41.7% (5/12). The longest duration of response (57 months) was seen in UPNII-11 ( Figure 1b) . The UPNII-09 with advanced refractory marginal zone lymphoma had achieved remission of skin and bone marrow after the first CART-20 cell infusion, but still had enlarged spleen. Thus, UPNII-09 received the consolidated second infusion, and the size of the spleen became gradually smaller and continued to shrink for up to 36 months (Figure 2a) . B-cell aplasia of this patient sustained for 150 weeks (Figure 2b and Supplementary Figure) . The treatment regimen was generally well tolerated. The acute adverse events included temporary chills and fever. The long-term monitoring for adverse events was for 5 years. The delayed adverse events related to CART-20 therapy were summarized in Table 2 . No Grade 4 toxicities were observed. Grade 3 herpes zoster due to long-term hypogammaglobulinemia was observed in UPNII-09 at 7 months after infusion. The decrease of immunoglobulin occurred in all patients with B-cell lack. We preventatively administered intravenous immunoglobulin to avoid hypogammaglobulinemia until the B-cell recovery. During the long follow-up periods, no patient was found to have susceptibility to viral infection or increase of other diseases incidence.
Some similar studies of CART cell therapy of B-cell NHL have been reported since 2001. 6, 7 At the 2016 annual meeting of the American Society of Hematology, updated data from Transcend NHL 001 trial showed that the longest observable PFS of patients with DLBCL was 9 months in those who achieved CR after treatment with CART-19 cells. 8 However, in our trials, the longest continued complete remission time of a patient with DLBCL was 57 months, which was comparable to the updated data from NCI group's trial of CART-19 in DLBCL. 3 In conclusion, long-duration CRs were observed in our CART-20 cell therapy. Compared to the outcomes of other clinical trials evaluating CAR-T cells in r/r B-NHL, our CART-20 cell therapy possibly made patients get longer PFS time. Our results provided unique evidence supporting the efficacy and safety of CART-20 in patients with r/r B-cell NHL. 
